DICE Therapeutics (DICE) Competitors

Nuvalent (NASDAQ:NUVL) and DICE Therapeutics (NASDAQ:DICE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.

Do institutionals and insiders believe in NUVL or DICE?

91.5% of DICE Therapeutics shares are owned by institutional investors. 14.8% of Nuvalent shares are owned by insiders. Comparatively, 4.9% of DICE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts prefer NUVL or DICE?

Nuvalent currently has a consensus target price of $44.50, suggesting a potential upside of 4.73%. DICE Therapeutics has a consensus target price of $62.60, suggesting a potential upside of 92.14%. Given DICE Therapeutics' higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
DICE Therapeutics	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Which has more risk and volatility, NUVL or DICE?

Nuvalent has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, DICE Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Does the media prefer NUVL or DICE?

In the previous week, Nuvalent had 3 more articles in the media than DICE Therapeutics. MarketBeat recorded 9 mentions for Nuvalent and 6 mentions for DICE Therapeutics. DICE Therapeutics' average media sentiment score of 0.82 beat Nuvalent's score of 0.12 indicating that DICE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DICE Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in NUVL or DICE?

DICE Therapeutics received 10 more outperform votes than Nuvalent when rated by MarketBeat users. However, 55.56% of users gave Nuvalent an outperform vote while only 48.39% of users gave DICE Therapeutics an outperform vote.

Company	Underperform	Outperform
Nuvalent	Outperform Votes 5 55.56%	Underperform Votes 4 44.44%
DICE Therapeutics	Outperform Votes 15 48.39%	Underperform Votes 16 51.61%

Which has higher earnings and valuation, NUVL or DICE?

Nuvalent has higher earnings, but lower revenue than DICE Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than DICE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$81.85 million	-$1.72	-24.70
DICE Therapeutics	$1.13 million	1,376.14	-$83.89 million	-$2.18	-14.94

Is NUVL or DICE more profitable?

DICE Therapeutics' return on equity of -22.01% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-25.63%	-24.59%
DICE Therapeutics	N/A	-22.01%	-20.70%

Summary

DICE Therapeutics beats Nuvalent on 9 of the 16 factors compared between the two stocks.